Cliff Asness's AGIO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 27,926 shares of Agios Pharmaceuticals, Inc. (AGIO) worth $754,002, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in AGIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 104,978 shares. Largest reduction occurred in Q1 2017, reducing 111,539 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Agios Pharmaceuticals (AGIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Agios Pharmaceuticals (AGIO) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -63,709 | Reduce 69.52% | 27,926 | $27.00 |
| Q3 2025 | -5,261 | Reduce 5.43% | 91,635 | $39.35 |
| Q2 2025 | +45,407 | Add 88.19% | 96,896 | $33.17 |
| Q1 2025 | +20,625 | Add 66.83% | 51,489 | $29.10 |
| Q4 2024 | -107,278 | Reduce 77.66% | 30,864 | $32.86 |
| Q3 2024 | +104,978 | Add 316.54% | 138,142 | $44.43 |
| Q2 2024 | +21,980 | Add 196.53% | 33,164 | $43.12 |
| Q1 2024 | +11,184 | New Buy | 11,184 | $29.23 |
| Q3 2023 | -7,717 | Sold Out | 0 | $0.00 |
| Q2 2023 | +7,717 | New Buy | 7,717 | $28.16 |
| Q4 2021 | -34,531 | Sold Out | 0 | $0.00 |
| Q3 2021 | +27,346 | Add 380.60% | 34,531 | $46.16 |
| Q2 2021 | +7,185 | New Buy | 7,185 | $53.31 |
| Q2 2019 | -5,392 | Sold Out | 0 | $0.00 |
| Q4 2018 | -7,017 | Reduce 56.55% | 5,392 | $46.18 |
| Q3 2018 | -402 | Reduce 3.14% | 12,409 | $77.12 |
| Q2 2018 | +12,811 | New Buy | 12,811 | $84.22 |
| Q2 2017 | -11,764 | Sold Out | 0 | $0.00 |
| Q1 2017 | -111,539 | Reduce 90.46% | 11,764 | $58.40 |
| Q4 2016 | -10,003 | Reduce 7.50% | 123,303 | $41.73 |
| Q3 2016 | +97,998 | Add 277.55% | 133,306 | $52.82 |
| Q2 2016 | +35,308 | New Buy | 35,308 | $41.89 |
| Q1 2016 | -20,454 | Sold Out | 0 | $0.00 |
| Q4 2015 | -3,073 | Reduce 13.06% | 20,454 | $64.93 |
| Q3 2015 | -21,734 | Reduce 48.02% | 23,527 | $70.60 |
| Q2 2015 | +7,161 | Add 18.80% | 45,261 | $111.13 |
| Q1 2015 | +35,400 | Add 1311.11% | 38,100 | $94.28 |
| Q4 2014 | -11,300 | Reduce 80.71% | 2,700 | $112.22 |
| Q3 2014 | +14,000 | New Buy | 14,000 | $61.36 |
Cliff Asness's Agios Pharmaceuticals Investment FAQs
Cliff Asness first purchased Agios Pharmaceuticals, Inc. (AGIO) in Q3 2014, acquiring 14,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Agios Pharmaceuticals, Inc. (AGIO) for 30 quarters since Q3 2014.
Cliff Asness's largest addition to Agios Pharmaceuticals, Inc. (AGIO) was in Q3 2024, adding 138,142 shares worth $6.14 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 27,926 shares of Agios Pharmaceuticals, Inc. (AGIO), valued at approximately $754,002.
As of the Q4 2025 filing, Agios Pharmaceuticals, Inc. (AGIO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Agios Pharmaceuticals, Inc. (AGIO) was 138,142 shares, as reported at the end of Q3 2024.